IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
US-0312939
(2015-05-27)
|
| 등록번호 |
US-10174289
(2019-01-08)
|
| 국제출원번호 |
PCT/US2015/032626
(2015-05-27)
|
| 국제공개번호 |
WO2015/183920
(2015-12-03)
|
|
발명자
/ 주소 |
- Wells, James Macormack
- McCracken, Kyle William
|
| 출원인 / 주소 |
- Children's Hospital Medical Center
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
0 인용 특허 :
61 |
초록
▼
Disclosed are methods of inducing formation of a gastric cells and/or a gastric tissue, such as in the form of a gastric organoid. The formation of gastric cells and/or tissue may be carried out by the activating and/or inhibiting of one or more signaling pathways within a precursor cell. Also discl
Disclosed are methods of inducing formation of a gastric cells and/or a gastric tissue, such as in the form of a gastric organoid. The formation of gastric cells and/or tissue may be carried out by the activating and/or inhibiting of one or more signaling pathways within a precursor cell. Also disclosed are methods for using the disclosed gastric cells, gastric tissues, and/or gastric organoids derived from precursor cells.
대표청구항
▼
1. A method of inducing formation of a gastric tissue, comprising the steps of: a) contacting a culture containing a mammalian definitive endoderm cell with an FGF signaling pathway activator, a Wnt signaling pathway activator, and a BMP inhibitor for at least two days or for a period of time suffic
1. A method of inducing formation of a gastric tissue, comprising the steps of: a) contacting a culture containing a mammalian definitive endoderm cell with an FGF signaling pathway activator, a Wnt signaling pathway activator, and a BMP inhibitor for at least two days or for a period of time sufficient to form SOX2+foregut cells;b) contacting said SOX2+foregut cells of step (a) with retinoic acid for a period of time sufficient to form three-dimensional foregut spheroids, wherein said spheroids express SOX2, PDX1, HNF1β, and HNF6;c) contacting said three-dimensional foregut spheroids of step (b) with retinoic acid, EGF, and a BMP inhibitor for a period of time sufficient for formation of a gastric organoid, wherein said gastric organoid is characterized by expression of MUC5AC, gastrin, ghrelin, 5-HT, and ChrA and the presence of cell types selected from one or more of antral mucous cells and endocrine cells. 2. The method of claim 1, wherein said precursor cell is selected from an embryonic stem cell, an embryonic germ cell, an induced pluripotent stem cell, a mesoderm cell, a definitive endoderm cell, a posterior endoderm cell, and a hindgut cell. 3. The method of claim 1, wherein said precursor cell is a definitive endoderm derived from contacting a pluripotent stem cell with one or more molecules selected from Activin, the BMP subgroups of the TGF-beta superfamily of growth factors; Nodal, Activin A, Activin B, BMP4, Wnt3a, and combinations thereof. 4. The method of claim 1, wherein said FGF signalling pathway is activated using an agent selected from one or more molecules selected from the group consisting of FGF1, FGF2, FGF3, FGF4, FGF10, FGF11, FGF12, FGF13, FGF14, FGF15, FGF16, FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and FGF23. 5. The method of claim 1, wherein said WNT signalling pathway is activated using an agent selected from one or more molecules selected from the group consisting of Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, and Wnt16. 6. The method of claim 1, wherein said activating step comprises contacting said precursor cell with both Wnt3a and FGF4 over a specified activation period. 7. The method of claim 1, wherein said inhibiting step comprises contacting said precursor cell with an agent that inhibits the BMP pathway, wherein said agent is selected from Noggin, Dorsomorphin, LDN189, DMH-1, and combinations thereof. 8. The method of claim 1, wherein said steps a) through c) are carried out for a period of time sufficient to cause formation of a foregut spheroid. 9. The method of claim 1 wherein the retinoic acid of step c) is administered in an amount of between about 0.2 uM to about 20 uM. 10. The method of claim 1, further comprising the step of culturing said activated precursor cell in vitro to form a 3-dimensional tissue structure. 11. The method of claim 1, wherein said activating and inhibiting steps are conducted in vitro. 12. The method of claim 1, wherein said activation period and said inhibition period overlap. 13. The method of claim 1, wherein said activation period and said inhibition period do not overlap. 14. The method of claim 1, wherein said activation period is between about 24 and about 120 hours.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.